Startup profile · funding coverage
Gate Bio
Biotech developing oral Molecular Gate medicines that eliminate disease-causing proteins.
Stage
series b
Status
private
Coverage
full
Why Gate Bio is interesting
Gate Bio's differentiated protein-secretion blockade attracted ARCH and a16z across a $60M Series A and $65M Series B.
Key facts
- Series A (2023): $60M co-led by Versant Ventures and a16z Bio + Health (/fund/andreessen-horowitz) with ARCH Venture Partners (/fund/arch-venture-partners) (BioCentury)
- Series B (2025): $65M with ARCH among existing investors (Gate Bio press)
Investors in our directory
Funds linked from Gate Bio's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Gate Bio's financing or category context.
FAQs about Gate Bio
Funding context and why this company shows up in venture coverage.
Gate Bio develops oral small-molecule drugs using its Molecular Gate platform, which blocks secretion of disease-causing proteins — a differentiated approach from traditional intracellular enzyme inhibition.
Gate Bio's $60M Series A (2023) was co-led by a16z Bio + Health (/fund/andreessen-horowitz) and Versant Ventures, with ARCH Venture Partners (/fund/arch-venture-partners). ARCH re-upped in the $65M Series B (2025).
Gate Bio is at Series B based on its 2025 $65M round.
Many disease-causing proteins are secreted rather than intracellular. Gate's Molecular Gate mechanism targets that class with oral medicines — a novel modality with broad therapeutic potential.
No. Gate Bio remains a private company.
Last updated: 2026-07-24